---
title: "Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294929837.md"
description: "Travere Therapeutics (TVTX) shares surged over 13% in after-hours trading following its second-quarter results. The biopharmaceutical company reported total revenue of $169.58 million, beating analyst estimates by 6.44%, driven by a 96% year-over-year increase in flagship drug FILSPARI sales to $141.1 million. Despite missing earnings per share expectations and widening net losses due to convertible note repurchase charges, strong revenue growth outweighed investor concerns, pushing the stock price up."
datetime: "2026-08-05T07:16:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294929837.md)
  - [en](https://longbridge.com/en/news/294929837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294929837.md)
generator: "portal-rs"
---

# Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

**Travere Therapeutics Inc.** (NASDAQ:TVTX) shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical company posted second-quarter revenue that beat analyst expectations, even as earnings missed.

## **Revenue Beat Drives Momentum**

For the period ended Jun. 30, Travere reported total revenue of $169.58 million, exceeding analyst expectations of $159.32 million by 6.44%. 

U.S. net product sales increased to $161.4 million, compared with $94.8 million a year earlier. Sales of flagship drug FILSPARI reached $141.1 million, marking a 96% year-over-year increase.

## **Wider Loss Doesn’t Dent Investor Enthusiasm**

Earnings per share for the biotech came in at a loss of $0.10, falling short of the analyst estimate of $0.23 by 143.5%.

Net loss also widened to $34.8 million from $12.8 million last year, partly reflecting a $40 million charge tied to 2029 convertible note repurchases.

## Trading Metrics, Technical Analysis

Travere has a market capitalization of $5.21 billion, with a 52-week high of $60.10 and a 52-week low of $15.60.

The stock has a Relative Strength Index (RSI) of 51.88.

Over the past 12 months, TVTX’s share price has gained 235.85%, and it has increased 90.09% over the past six months.

The mid-cap stock is currently trading at about 91% of its 52-week range, remaining near its annual high.

TVTX’s long-term trend and strong positioning indicate continued upside potential.

**Price Action:** The healthcare stock closed the regular session on Tuesday at $56.02, up 1.89%, according to Benzinga Pro.

With strong Momentum in the 97th percentile, **Benzinga’s Edge Stock Rankings** indicate that TVTX has a positive price trend across all time frames.

***Disclaimer:*** *This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.*

 **Read Also: AppLovin (APP) Stock Jumps Over 3% After Hours: Here's Why It Is Trending** 

*Photo Courtesy: ImageSymphony on Shutterstock.com*

### Related Stocks

- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [APP.US](https://longbridge.com/en/quote/APP.US.md)

## Related News & Research

- [Travere Therapeutics Q2 product sales rise on FILSPARI demand](https://longbridge.com/en/news/294864809.md)
- [Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296673080.md)
- [Electra Therapeutics, SIRP-Targeted Precision Medicines, Files for Nasdaq Global Select Market IPO](https://longbridge.com/en/news/297364174.md)
- [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md)
- [Antibody biotech Electra Therapeutics files for a $100 million IPO](https://longbridge.com/en/news/297374842.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**